The therapeutic value of these agents for breast and gastric carcinomas is clear, whereas they do not seem to be so effective in UCs.80 The second and more recent indication is to investigate any level of HER2 expression in TCs, to determine the eligibility of patients for novel treatments, recently developed to target HER2+ UC cells, such as ADCs.80,81 For example, disitamab vedotin (RC48) is an ADC composed of an anti-HER2 antibody bound to a cytotoxic agent with antineoplastic activity. This evidence concerns the gene ERBB2 and gastric carcinoma.